Abstract:Niemann–Pick Type C (NPC) represents an autosomal recessive disorder with an incidence rate of 1 in 150,000 live births, classified within lysosomal storage diseases (LSDs). The abnormal accumulation of unesterified cholesterol characterizes the pathophysiology of NPC. This phenomenon is not unique to NPC, as analogous accumulations have also been observed in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Interestingly, disturbances in the folding of the mutant protein NPC1 I1061T are accompanied by the aggregation of proteins such as hyperphosphorylated tau, α-synuclein, TDP-43, and β-amyloid peptide. These accumulations suggest potential disruptions in proteostasis, a regulatory process encompassing four principal mechanisms: synthesis, folding, maintenance of folding, and protein degradation. The dysregulation of these processes leads to excessive accumulation of abnormal proteins that impair cell function and trigger cytotoxicity. This comprehensive review delineates reported alterations across proteostasis mechanisms in NPC, encompassing changes in processes from synthesis to degradation. Additionally, it discusses therapeutic interventions targeting pharmacological facets of proteostasis in NPC. Noteworthy among these interventions is valproic acid, a histone deacetylase inhibitor (HDACi) that modulates acetylation during NPC1 synthesis. In addition, various therapeutic options addressing protein folding modulation, such as abiraterone acetate, DHBP, calnexin, and arimoclomol, are examined. Additionally, treatments impeding NPC1 degradation, exemplified by bortezomib and MG132, are explored as potential strategies. This review consolidates current knowledge on proteostasis dysregulation in NPC and underscores the therapeutic landscape targeting diverse facets of this intricate process.

New Cellular Models for Niemann–Pick Type C Disease

Alterations in Proteostasis Mechanisms in Niemann–Pick Type C Disease

Development and Validation of a New Genotype-Phenotype Correlation for Niemann-Pick Disease Type C1

Increased NPC1 mRNA in skin fibroblasts from Niemann-Pick disease type C patients.

Myelin Defects in Niemann–Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives

Understanding the phenotypic variability in Niemann-Pick disease type C (NPC): a need for precision medicine

Importance of the biochemical investigations for the functional characterization of a NPC1 variant identified by exome sequencing

Cutting Edge: Impaired Glycosphingolipid Trafficking and NKT Cell Development in Mice Lacking Niemann-Pick Type C1 Protein

A Genetic Modifier of Niemann-Pick Disease, Type C1

Genetic and Clinical Characterization of Niemann-Pick Disease Type C with Homozygous NPC1 gene mutation: Insights from whole exome sequencing and advanced neuroimaging of two familial cases

Myeloid cell–specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease

Molecular Characterization of the NPC1L1 Variants Identified from Cholesterol Low Absorbers

Experience of the NPC Brazil Network with a Comprehensive Program for the Screening and Diagnosis of Niemann-Pick Disease Type C

Abnormal gene expression in cerebellum of Npc1−/− mice during postnatal development

Clinical, ocular motor, and imaging profile of Niemann-Pick type C heterozygosity

Genetic and laboratory diagnostic approach in Niemann Pick disease type C

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Defective iron homeostasis and hematological abnormalities in Niemann-Pick disease type C1

Endo-lysosomal dysfunction and neuronal–glial crosstalk in Niemann–Pick type C disease

Differential Interferon Signaling Regulation and Oxidative Stress Responses in the Cerebral Cortex and Cerebellum Could Account for the Spatiotemporal Pattern of Neurodegeneration in Niemann–Pick Disease Type C

Altered localization and functionality of TAR DNA Binding Protein 43 (TDP-43) in niemann- pick disease type C